Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-07-21
1998-03-17
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
424 854, 424 857, 514 2, 514 21, 514386, A61K 31415, A61K 31505
Patent
active
057287074
ABSTRACT:
Methods and compositions for the prevention and/or inhibition of primary and secondary metastatic neoplasms are described. Individuals at a high risk of developing neoplasia and/or cancer patients undergoing conventional therapies may be treated with an effective dose of a salt of aminoimidazole carboxamide.
REFERENCES:
Al-Safi, S.A., and Maddocks, J.L., 1984, "Azathioprine and 6-mercaptopurine (6-MP) suppress the human mixed lymphocyte reaction (MLR) by different mechanisms", Br. J. Clin. Pharmac. 17:417-422.
Bonadonna, G., and Valagussa, P., 1988, "Adjuvant chemotherapy for breast cancer", Semin. Surg. Oncol. 4:250-255.
DeVita, V.T., et al., 1975, "Combination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancer", Cancer 35:98-110.
Frei, III, E., 1972, "Combination cancer therapy: Presidential address", Cancer Res. 32:2593-2607.
Hakala et al., 1964, "Prevention of the growth-inhibitory effect of 6-mercaptopurine by 4-aminoimidazole-5-carboxamide" Biochim Biophys Acta 80:665-668.
Hano, K., and Akashi, A., 1964, "Influences of anticancer agents on the metabolism of .epsilon.-aminolevulinic acid in normal and tumor-bearing mice", Gann 55:25-40.
Harris, C.C., 1979, "A delayed complication of cancer therapy--cancer", J. Natl. Cancer Inst. 63:275-277.
Horrobin, D.F., et al., 1978, "Thromboxane A2: A key regulator of prostaglandin biosynthesis and of interactions between prostaglandins, calcium and cyclic nucleotides", Med. Hypothesis 4:178-186.
Karmali, R.A., 1983, "Prostaglandins and cancer", CA Cancer J Clin. 33:322-332.
Karmali, R.A., et al., 1993, "Plant and marine n-3 fatty acids inhibit experimental metastasis of rat mammary adenocarcinoma cells", Prost. Leuk. Essential & Fatty Acids 48:309-314.
Myers, C.E., 1992, "Anthracyclines", Cancer Chemother. Biol. Response Modif. 13:45-52.
Rutty, C.J., et al., 1984, "The species dependent pharmacokinetics of DTIC", Br. J. Cancer 48:140.
Shealy, Y.F., and Kranth, C.A., 1966, "Imidazoles. II. 5(or 4)-(monosubstituted trizeno)imidazole-4(or 5)-carboxamides", J. Med. Chem. 9:34-38.
Shealy, Y.F., et al., 1962, "Imidazoles. I. Coupling reactions of 5-diazoimidazole-4-carboxamide", J. Org. Chem. 27:2150-2154.
Shealy, Y.F., et al., 1961, "Synthesis of potential anticancer agents. XXIX. 5-Diazoimidazole-4-carboxamide and 5-Diazo-v-triazole-4-carboxamide" J. Org. Chem. 26:2396-2401.
Shealy, Y.F., et al., 1962, "Antitumor activity of triazenoimidazoles", Biochem. Pharmacol. 11:674-676.
Terao, S., et al., 1985, "Thromboxane synthetase inhibitors: Design and synthesis of a novel series of .omega.-pyridylalkenoic acid", Advances in Prostagl. Thromb. Leuk Res. 15:315-317.
Weiss, R.B., and DeVita, Jr., V.T., 1979, "Multimodal primary cancer treatment (Adjuvant chemotherapy): Current results and future prospects", Ann. Intern. Med. 91:251-260.
Constantia Gruppe
Raymond Richard L.
LandOfFree
Treatment and prevention of primary and metastatic neoplasms wit does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment and prevention of primary and metastatic neoplasms wit, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment and prevention of primary and metastatic neoplasms wit will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-957923